FindTrial
Sign In

Effect of Vitamin D supplementation in patients with schizophrenia

The Effect of vitamin D supplementation on clinical ,electroencephalographic and metabolic outcomes in schizophrenia patients under clozapine treatment :A Hospital based controlled study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/096868
Enrollment
40
Registered
2025-11-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F20- Schizophrenia

Interventions

Intervention1: Vitamin D supplementation: 20 patients on CLOZAPINE receiving Vitamin D 60K IU once a week orally for 4 weeks Control Intervention1: Clozapine as usual group: 20 patients on CLOZAPINE o

Sponsors

Central Institute of Psychiatry, Ranchi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient with diagnosis of Schizophrenia in ICD 2. Illness duration of atleast 2 years 3. Patients providing informed consent for the study

Exclusion criteria

Exclusion criteria: 1. Any other comorbid psychiatric diagnosis 2. Any comorbid substance use 3. Significant current or past medical illness 4. Known hypersensitivity to Vitamin D

Design outcomes

Primary

MeasureTime frame
Changes in symptomatology, metabolic parameters (lipid profile, glucose metabolism), and low-frequency electroencephalographic activities (delta and theta power) in patients with schizophrenia on Clozapine therapy receiving weekly vitamin D supplementation (60,000 IU)Timepoint: 0, 2nd and 4th week—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactUmesh S

Central Institute of Psychiatry, Ranchi

umesh.yes@hotmail.com9771702403

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026